Skip to main content

Lantheus (LNTH) Receives a Buy from TD Cowen

Tipranks - Tipranks - Fri Jan 30, 6:40AM CST

TD Cowen analyst Tara Bancroft reiterated a Buy rating on Lantheus today and set a price target of $75.00.

Claim 50% Off TipRanks Premium

Bancroft covers the Healthcare sector, focusing on stocks such as Disc Medicine, Ocular Therapeutix, and Lantheus. According to TipRanks, Bancroft has an average return of 19.2% and a 45.86% success rate on recommended stocks.

In addition to TD Cowen, Lantheus also received a Buy from TipRanks – OpenAI’s OpenAI Drug Manufacturers – Specialty and Generic in a report issued yesterday. However, on the same day, TipRanks – DeepSeek reiterated a Hold rating on Lantheus (NASDAQ: LNTH).

See Insiders’ Hot Stocks on TipRanks >>

Based on Lantheus’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $384.01 million and a net profit of $27.77 million. In comparison, last year the company earned a revenue of $378.73 million and had a net profit of $131.09 million

Read More on LNTH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).